MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$244,369K
Proceeds from stock
option exercises
$1,979K
Proceeds from issuance of
common stock under espp
$1,313K
Net cash provided by
financing activities
$245,264K
Canceled cashflow
$2,397K
Net (decrease)
increase in cash, cash...
-$13,737K
Canceled cashflow
$245,264K
Maturities of investments
$252,500K
Stock-based compensation
expense
$25,037K
Prepaid expenses and
other assets
-$1,787K
Depreciation
$1,220K
Issuance costs
associated with financings
$2,397K
Net cash (used in)
provided by investing...
-$148,031K
Canceled cashflow
$252,500K
Net cash used in
operating activities
-$110,970K
Canceled cashflow
$28,044K
Purchases of investments
$399,819K
Acquisitions of property and
equipment
$712K
Net loss
-$129,468K
Accounts payable and
accrued other...
-$7,246K
Accretion of discount on
investments, net
$2,300K
Back
Back
Cash Flow
source: myfinsight.com
Oric Pharmaceuticals, Inc. (ORIC)
Oric Pharmaceuticals, Inc. (ORIC)